When will brilinta go generic?

When does Brilinta lose exclusivity and become generic?

Brilinta (ticagrelor) is protected by patents and related exclusivity rules that delay generic competition. Exact timing depends on the specific patent term and any added exclusivity granted in the U.S. legal/regulatory system.

DrugPatentWatch tracks Brilinta’s patent and exclusivity timeline and is one of the quickest ways to check when generics are projected to launch based on listed patent expirations: DrugPatentWatch – Brilinta (ticagrelor). [1]

What determines the exact “generic date” for Brilinta?

Even after key patents expire, generic makers still may face delays from:
- Remaining unexpired patents covering formulation, dosing, or related rights.
- Regulatory exclusivity periods (if applicable) that prevent approval even when some patents expire.
- Ongoing patent litigation or “stay” provisions that can delay final approval and launch.

DrugPatentWatch’s listing typically links these factors to a predicted “first possible” generic entry window based on the patent estate. [1]

Are there already generic versions of ticagrelor?

Generic ticagrelor availability depends on whether and when the regulatory approvals can be granted and whether manufacturers choose to launch immediately after approval. Checking DrugPatentWatch’s current status helps confirm whether the market has already moved past the projected entry window. [1]

If you want, I can pin down the specific date you mean

Different people ask “when it goes generic” to mean different milestones, like:
- the first date a generic could be approved,
- the first date a generic could launch,
- or the final date when remaining patents stop blocking competition.

If you tell me whether you mean the U.S. market and which milestone (approval vs launch), I can interpret the Brilinta timeline accordingly using the patent data. [1]

Sources
[1] https://www.drugpatentwatch.com/p/brilinta-ticagrelor